207_Combined course Presentations

RADITUX trial: final results

Overall Survival

 OS was remarkably high (37% @ 5 years)

 Hypofractionated RT + daily might contribute to increase OS in locally advanced NSCLC  No positive results for Cetuximab and RT in stage III NSCLC so far

Median OS 33 (arm A) vs 30 (arm B) months p-value 0.722

Walraven I. et al. Radiot Oncol 2016;116